Synchrony Medical Attracts $5 Million in Funding for Commercial Expansion

Synchrony Medical has closed an oversubscribed $5 million funding round led by Edge Medical Ventures with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors.

The money will help the company accelerate U.S. commercial expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty Airway Clearance System.

“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health,” Synchrony Medical CEO Anat Shani stated. “Supported by our investors and new board members, we’re well-positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation.”

For millions living with chronic lung conditions, airway clearance is essential to managing symptoms, preventing infections, and slowing disease progression. The LibAirty system delivers this vital therapy through a daily home treatment that has shown the ability to clear twice as much sputum as conventional therapies with enhanced user comfort and satisfaction. Since its commercial launch late last year, LibAirty has received an enthusiastic response from both patients and clinicians, demonstrating immediate impact on daily condition management.

In conjunction with the funding, Synchrony appointed Kevin Kotler, general partner of Broadfin Holdings, and Elad Duschak, strategic advisor to CBG for Healthcare, to the company’s Board of Directors.

“The LibAirty System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth,” Kotler said. “We look forward to working with the team to scale nationwide and create meaningful value for both patients and shareholders.”

Synchrony will continue to expand its U.S. team and operations from its Jersey City, N.J., headquarters. The financing includes $1 million from the NJEDA through the New Jersey Innovation Evergreen Fund (NJIEF)’s co-investment with Edge Medical Ventures.

“Synchrony exemplifies the type of innovation we seek to support, addressing an unmet clinical need through strong clinical foundations and a clear path to transforming patient care,” Synchrony Medical Chairman/Edge Medical Ventures Managing Partner Shai Policker shared. “This demonstrates how Edge’s transatlantic presence, combined with the company’s proven execution capabilities, can establish a new standard of care and bring it to market.”

“As partners of EdgeLabs (formerly MEDX Xelerator), we are proud to support Synchrony from its early stages of development and witness its progress,” Consensus Business Group Chairman Vincent Tchenguiz stated. “We are pleased to continue supporting this medical innovation and make it more widely available for patients.”

Synchrony Medical is a respiratory care technology company providing advanced at-home airway clearance therapy. The company’s U.S. Food and Drug Administration-cleared LibAirty Airway Clearance System transforms respiratory therapy into an easy-to-manage daily routine that patients can perform independently at home. Developed in collaboration with leading pulmonologists at Sheba Medical Center, LibAirty was founded through Edge Medical Ventures’ EdgeLabs (formerly MEDX Xelerator) and is supported by the Israel Innovation Authority. Synchrony Medical is headquartered in New Jersey and maintains additional operations in Or Yehuda, Israel.